Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling-Reference-Cited by-同舟云学术

Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling

Published:2022-05-05 Issue:7 Volume:61 Page:997-1012
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Dubinsky Samuel,Malik Paul,Hajducek Dagmar M.,Edginton Andrea^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-022-01121-6.pdf

Reference97 articles.

1. Purcell CA, Abebe M, Adebayo OM, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–33. https://doi.org/10.1016/S0140-6736(20)30045-3.

2. KDIGO (Kidney Disease: Improving Global Outcomes). Acute kidney injury. 2012. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf. Accessed 18 Mar 2022.

3. Manley HJ, Cannella CA, Bailie GR, St Peter WL. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669–80. https://doi.org/10.1053/j.ajkd.2005.07.001.

4. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. Renal transporters in drug development. Annu Rev Pharmacol Toxicol. 2013;53:503–29. https://doi.org/10.1146/annurev-pharmtox-011112-140317.

5. Torres AM, Dnyanmote AV, Granados JC, Nigam SK. Renal and non-renal response of ABC and SLC transporters in chronic kidney disease. Expert Opin Drug Metab Toxicol. 2021;17(5):515–42. https://doi.org/10.1080/17425255.2021.1899159.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling;CPT: Pharmacometrics & Systems Pharmacology;2024-01-10

2. Physiologically based pharmacokinetic modeling to predict OAT3-mediated drug-drug interactions of meropenem in varying stages of chronic kidney disease;European Journal of Pharmaceutical Sciences;2023-04

3. Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward;Biopharmaceutics & Drug Disposition;2022-12-14